Pharma Journalist 9038 posts 0 comments

SMi reports: Registration is now open for the Highly Potent Active Pharmaceutical Ingredients Conference, which will convene in London on 11th-12th May 2020. SMi Group are pleased to…
Read More...

Alnylam Pharmaceuticals announced that the Company has initiated a rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumasiran, an…
Read More...

Zymeworks Inc. announced the initiation of a Phase 2 trial evaluating ZW25 combination therapy and an agreement with Pfizer which advances the study. Zymeworks’ HER2-targeted bispecific…
Read More...

eFFECTOR Therapeutics and Pfizer Inc. announced an exclusive worldwide license and collaboration agreement to develop small-molecule inhibitors of eukaryotic initiation factor 4E…
Read More...

Eli Lilly and Company and Dermira, Inc. announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction.…
Read More...

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, reported that the previously…
Read More...

Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, and Cellectis, a clinical-stage biopharmaceutical company focused on…
Read More...

SMi Reports: Interactive workshop overview for SMi's 22nd Annual Superbugs & Superdrugs Conference, London in March 2020 SMi’s highly anticipated 22nd Annual Superbugs &…
Read More...

PPD, Inc. (PPD) has expanded its operations and leadership team in China to provide enhanced clinical development, laboratory, regulatory, site conduct, patient access and post-approval…
Read More...

Almirall, S.A. and WuXi Biologics have announced the signing of an agreement. Through this collaboration Almirall embarks on its strategy to develop highly innovative biologic products…
Read More...